Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Takeda Pharmaceutical announces U.S. commercial availability of Livtencity » 09:51
12/02/21
12/02
09:51
12/02/21
09:51
TAK

Takeda Pharmaceutical

$13.38 /

+0.2 (+1.52%)

Takeda Pharmaceutical…

Takeda Pharmaceutical announced the United States commercial availability of Livtencity, the first and only treatment for adults and pediatric patients with post-transplant cytomegalovirus infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet. Livtencity an orally bioavailable anti-CMV compound, became available for prescription on December 2, just over a week after the U.S. FDA approval which took place on November 23.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$13.38 /

+0.2 (+1.52%)

TAK Takeda Pharmaceutical
$13.38 /

+0.2 (+1.52%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
TAK Takeda Pharmaceutical
$13.38 /

+0.2 (+1.52%)

TAK Takeda Pharmaceutical
$13.38 /

+0.2 (+1.52%)

TAK Takeda Pharmaceutical
$13.38 /

+0.2 (+1.52%)

Over a week ago
Hot Stocks
FDA approves Takeda's Livtencity for post-transplant CMV » 16:52
11/23/21
11/23
16:52
11/23/21
16:52
TAK

Takeda Pharmaceutical

$13.80 /

-0.015 (-0.11%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration approved Livtencity, maribavir, as the first drug for treating adults and pediatric patients with post-transplant cytomegalovirus or CMV, infection/disease that does not respon to available antiviral treatment for CMV. Livtencity works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. "Transplant recipients are at a much greater risk for complications and death when faced with a cytomegalovirus infection," said John Farley, M.D., M.P.H., director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research. "Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern. Today's approval helps meet a significant unmet medical need by providing a treatment option for this patient population." CMV is a type of herpes virus that commonly causes infection in patients after a stem cell or organ transplant. CMV infection can lead to CMV disease and have a major negative impact on transplant recipients, including loss of the transplanted organ and death. Livtencity's safety and efficacy were evaluated in a Phase 3, multicenter, open-label, active-controlled trial that compared Livtencity with a treatment assigned by a researcher running the study, which could include one or two of the following antivirals used to treat CMV: ganciclovir, valganciclovir, foscarnet or cidofovir. In the study, 352 transplant recipients with CMV infections who did not respond to treatment randomly received Livtencity or treatment assigned by a researcher for up to eight weeks. Reference Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

Hot Stocks
FDA approves Takeda's Livtencity for post-transplant CMV » 16:52
11/23/21
11/23
16:52
11/23/21
16:52
TAK

Takeda Pharmaceutical

$13.80 /

-0.015 (-0.11%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration approved Livtencity, maribavir, as the first drug for treating adults and pediatric patients with post-transplant cytomegalovirus or CMV, infection/disease that does not respon to available antiviral treatment for CMV. Livtencity works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. "Transplant recipients are at a much greater risk for complications and death when faced with a cytomegalovirus infection," said John Farley, M.D., M.P.H., director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research. "Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern. Today's approval helps meet a significant unmet medical need by providing a treatment option for this patient population." CMV is a type of herpes virus that commonly causes infection in patients after a stem cell or organ transplant. CMV infection can lead to CMV disease and have a major negative impact on transplant recipients, including loss of the transplanted organ and death. Livtencity's safety and efficacy were evaluated in a Phase 3, multicenter, open-label, active-controlled trial that compared Livtencity with a treatment assigned by a researcher running the study, which could include one or two of the following antivirals used to treat CMV: ganciclovir, valganciclovir, foscarnet or cidofovir. In the study, 352 transplant recipients with CMV infections who did not respond to treatment randomly received Livtencity or treatment assigned by a researcher for up to eight weeks. Reference Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

TAK Takeda Pharmaceutical
$13.80 /

-0.015 (-0.11%)

Conference/Events
STAT to hold a virtual summit » 04:55
11/18/21
11/18
04:55
11/18/21
04:55
ALLO

Allogene Therapeutics

$19.05 /

-0.31 (-1.60%)

, AMGN

Amgen

$205.88 /

+0.51 (+0.25%)

, CSLLY

CSL

$112.45 /

-0.03 (-0.03%)

, EXAS

Exact Sciences

$88.36 /

-3.12 (-3.41%)

, GSK

GlaxoSmithKline

$42.02 /

+0.095 (+0.23%)

, LLY

Eli Lilly

$261.12 /

+3.435 (+1.33%)

, MRK

Merck

$82.60 /

-1.535 (-1.82%)

, MRNA

Moderna

$242.22 /

+8.25 (+3.53%)

, PFE

Pfizer

$50.88 /

+1.305 (+2.63%)

, SBTX

Silverback Therapeutics

$8.50 /

-0.015 (-0.18%)

, SNY

Sanofi

$51.04 /

+0.14 (+0.28%)

, TAK

Takeda Pharmaceutical

$14.05 /

-0.05 (-0.35%)

, URGN

UroGen Pharma

$13.09 /

-0.56 (-4.10%)

STAT Summit 2021 to be…

STAT Summit 2021 to be held on November 16-18.Webcast Link

ShowHide Related Items >><<
URGN UroGen Pharma
$13.09 /

-0.56 (-4.10%)

TAK Takeda Pharmaceutical
$14.05 /

-0.05 (-0.35%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

SBTX Silverback Therapeutics
$8.50 /

-0.015 (-0.18%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

MRNA Moderna
$242.22 /

+8.25 (+3.53%)

MRK Merck
$82.60 /

-1.535 (-1.82%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

GSK GlaxoSmithKline
$42.02 /

+0.095 (+0.23%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

CSLLY CSL
$112.45 /

-0.03 (-0.03%)

AMGN Amgen
$205.88 /

+0.51 (+0.25%)

ALLO Allogene Therapeutics
$19.05 /

-0.31 (-1.60%)

ALLO Allogene Therapeutics
$19.05 /

-0.31 (-1.60%)

10/19/21 Cowen
Allogene Therapeutics assumed with an Outperform at Cowen
10/12/21 JMP Securities
Allogene Therapeutics price target lowered to $27 from $53 at JMP Securities
10/08/21
Fly Intel: Top five analyst downgrades
10/08/21 Jefferies
Jefferies lowers Allogene price target to $30, says 'buy this dip'
AMGN Amgen
$205.88 /

+0.51 (+0.25%)

11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
CSLLY CSL
$112.45 /

-0.03 (-0.03%)

10/05/21 Jefferies
CSL upgraded to Buy from Hold at Jefferies
08/18/21 Jefferies
CSL downgraded to Hold from Buy at Jefferies
06/24/21 Credit Suisse
CSL downgraded to Neutral from Outperform at Credit Suisse
06/23/21 Citi
CSL downgraded to Neutral from Buy at Citi
EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
GSK GlaxoSmithKline
$42.02 /

+0.095 (+0.23%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
MRK Merck
$82.60 /

-1.535 (-1.82%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
MRNA Moderna
$242.22 /

+8.25 (+3.53%)

11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
11/08/21 Wolfe Research
Moderna initiated with an Outperform at Wolfe Research
11/05/21 Jefferies
Moderna price target lowered to $325 from $375 at Jefferies
11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
PFE Pfizer
$50.88 /

+1.305 (+2.63%)

11/17/21 Benchmark
Trillium Therapeutics downgraded to Hold from Buy at Benchmark
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
SBTX Silverback Therapeutics
$8.50 /

-0.015 (-0.18%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
SNY Sanofi
$51.04 /

+0.14 (+0.28%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
TAK Takeda Pharmaceutical
$14.05 /

-0.05 (-0.35%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
URGN UroGen Pharma
$13.09 /

-0.56 (-4.10%)

04/27/21 H.C. Wainwright
UroGen Pharma price target lowered to $50 from $57 at H.C. Wainwright
URGN UroGen Pharma
$13.09 /

-0.56 (-4.10%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

SBTX Silverback Therapeutics
$8.50 /

-0.015 (-0.18%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

MRNA Moderna
$242.22 /

+8.25 (+3.53%)

MRK Merck
$82.60 /

-1.535 (-1.82%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

GSK GlaxoSmithKline
$42.02 /

+0.095 (+0.23%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

AMGN Amgen
$205.88 /

+0.51 (+0.25%)

ALLO Allogene Therapeutics
$19.05 /

-0.31 (-1.60%)

  • 04
    Dec
TAK Takeda Pharmaceutical
$14.05 /

-0.05 (-0.35%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

MRNA Moderna
$242.22 /

+8.25 (+3.53%)

MRK Merck
$82.60 /

-1.535 (-1.82%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

GSK GlaxoSmithKline
$42.02 /

+0.095 (+0.23%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

TAK Takeda Pharmaceutical
$14.05 /

-0.05 (-0.35%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

SBTX Silverback Therapeutics
$8.50 /

-0.015 (-0.18%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

MRNA Moderna
$242.22 /

+8.25 (+3.53%)

MRK Merck
$82.60 /

-1.535 (-1.82%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

GSK GlaxoSmithKline
$42.02 /

+0.095 (+0.23%)

EXAS Exact Sciences
$88.36 /

-3.12 (-3.41%)

AMGN Amgen
$205.88 /

+0.51 (+0.25%)

ALLO Allogene Therapeutics
$19.05 /

-0.31 (-1.60%)

TAK Takeda Pharmaceutical
$14.05 /

-0.05 (-0.35%)

SBTX Silverback Therapeutics
$8.50 /

-0.015 (-0.18%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

MRNA Moderna
$242.22 /

+8.25 (+3.53%)

MRK Merck
$82.60 /

-1.535 (-1.82%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

GSK GlaxoSmithKline
$42.02 /

+0.095 (+0.23%)

AMGN Amgen
$205.88 /

+0.51 (+0.25%)

ALLO Allogene Therapeutics
$19.05 /

-0.31 (-1.60%)

Hot Stocks
Denali Therapeutics announces Takeda to exercise option to co-develop DNL593 » 08:32
11/17/21
11/17
08:32
11/17/21
08:32
DNLI

Denali Therapeutics

$50.43 /

+0.3 (+0.60%)

, TAK

Takeda Pharmaceutical

$14.10 /

-0.32 (-2.22%)

Denali Therapeutics…

Denali Therapeutics (DNLI) announced that its strategic partner Takeda Pharmaceutical Company (TAK) has exercised an option, pursuant to an existing collaboration agreement between the two companies, to co-develop and co-commercialize DNL593, an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin, FTD-GRN. "We are excited to advance our collaboration with Takeda on the development of DNL593 as a potential treatment for people with FTD-GRN," said Denali's Chief Executive Officer, Ryan Watts, Ph.D. "Pending acceptance of regulatory submissions, DNL593 will be the sixth therapeutic candidate from our broad pipeline, and our second Transport Vehicle-enabled molecule, in clinical development. This progress underscores the potential of our TV platform technology, which is designed to enable and enhance delivery of biologic therapeutics to the brain for the treatment of neurodegenerative diseases."

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

DNLI Denali Therapeutics
$50.43 /

+0.3 (+0.60%)

DNLI Denali Therapeutics
$50.43 /

+0.3 (+0.60%)

11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
07/26/21 Stifel
Denali DNL310 data 'noisy and trending in wrong direction,' says Stifel
TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
DNLI Denali Therapeutics
$50.43 /

+0.3 (+0.60%)

TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

DNLI Denali Therapeutics
$50.43 /

+0.3 (+0.60%)

TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

Conference/Events
STAT to hold a virtual summit » 04:55
11/17/21
11/17
04:55
11/17/21
04:55
ALLO

Allogene Therapeutics

$19.37 /

+0.54 (+2.87%)

, AMGN

Amgen

$205.37 /

-1.84 (-0.89%)

, CSLLY

CSL

$112.48 /

-1.06 (-0.93%)

, EXAS

Exact Sciences

$91.45 /

+1.56 (+1.74%)

, GSK

GlaxoSmithKline

$42.45 /

-0.71 (-1.65%)

, LLY

Eli Lilly

$257.69 /

-0.58 (-0.22%)

, MRK

Merck

$84.13 /

+0.43 (+0.51%)

, MRNA

Moderna

$234.20 /

-0.88 (-0.37%)

, PFE

Pfizer

$49.57 /

-0.08 (-0.16%)

, SBTX

Silverback Therapeutics

$8.52 /

-0.185 (-2.13%)

, SNY

Sanofi

$50.90 /

-0.21 (-0.41%)

, TAK

Takeda Pharmaceutical

$14.10 /

-0.32 (-2.22%)

, URGN

UroGen Pharma

$13.64 /

-1.085 (-7.37%)

STAT Summit 2021 to be…

STAT Summit 2021 to be held on November 16-18.Webcast Link

ShowHide Related Items >><<
URGN UroGen Pharma
$13.64 /

-1.085 (-7.37%)

TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

SNY Sanofi
$50.90 /

-0.21 (-0.41%)

SBTX Silverback Therapeutics
$8.52 /

-0.185 (-2.13%)

PFE Pfizer
$49.57 /

-0.08 (-0.16%)

MRNA Moderna
$234.20 /

-0.88 (-0.37%)

MRK Merck
$84.13 /

+0.43 (+0.51%)

LLY Eli Lilly
$257.69 /

-0.58 (-0.22%)

GSK GlaxoSmithKline
$42.45 /

-0.71 (-1.65%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

CSLLY CSL
$112.48 /

-1.06 (-0.93%)

AMGN Amgen
$205.37 /

-1.84 (-0.89%)

ALLO Allogene Therapeutics
$19.37 /

+0.54 (+2.87%)

ALLO Allogene Therapeutics
$19.37 /

+0.54 (+2.87%)

10/19/21 Cowen
Allogene Therapeutics assumed with an Outperform at Cowen
10/12/21 JMP Securities
Allogene Therapeutics price target lowered to $27 from $53 at JMP Securities
10/08/21
Fly Intel: Top five analyst downgrades
10/08/21 Jefferies
Jefferies lowers Allogene price target to $30, says 'buy this dip'
AMGN Amgen
$205.37 /

-1.84 (-0.89%)

11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
CSLLY CSL
$112.48 /

-1.06 (-0.93%)

10/05/21 Jefferies
CSL upgraded to Buy from Hold at Jefferies
08/18/21 Jefferies
CSL downgraded to Hold from Buy at Jefferies
06/24/21 Credit Suisse
CSL downgraded to Neutral from Outperform at Credit Suisse
06/23/21 Citi
CSL downgraded to Neutral from Buy at Citi
EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
GSK GlaxoSmithKline
$42.45 /

-0.71 (-1.65%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
LLY Eli Lilly
$257.69 /

-0.58 (-0.22%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
MRK Merck
$84.13 /

+0.43 (+0.51%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
MRNA Moderna
$234.20 /

-0.88 (-0.37%)

11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
11/08/21 Wolfe Research
Moderna initiated with an Outperform at Wolfe Research
11/05/21 Jefferies
Moderna price target lowered to $325 from $375 at Jefferies
11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
PFE Pfizer
$49.57 /

-0.08 (-0.16%)

11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
SBTX Silverback Therapeutics
$8.52 /

-0.185 (-2.13%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
SNY Sanofi
$50.90 /

-0.21 (-0.41%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
URGN UroGen Pharma
$13.64 /

-1.085 (-7.37%)

04/27/21 H.C. Wainwright
UroGen Pharma price target lowered to $50 from $57 at H.C. Wainwright
URGN UroGen Pharma
$13.64 /

-1.085 (-7.37%)

SNY Sanofi
$50.90 /

-0.21 (-0.41%)

SBTX Silverback Therapeutics
$8.52 /

-0.185 (-2.13%)

PFE Pfizer
$49.57 /

-0.08 (-0.16%)

MRNA Moderna
$234.20 /

-0.88 (-0.37%)

MRK Merck
$84.13 /

+0.43 (+0.51%)

LLY Eli Lilly
$257.69 /

-0.58 (-0.22%)

GSK GlaxoSmithKline
$42.45 /

-0.71 (-1.65%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

AMGN Amgen
$205.37 /

-1.84 (-0.89%)

ALLO Allogene Therapeutics
$19.37 /

+0.54 (+2.87%)

  • 04
    Dec
TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

SNY Sanofi
$50.90 /

-0.21 (-0.41%)

PFE Pfizer
$49.57 /

-0.08 (-0.16%)

MRNA Moderna
$234.20 /

-0.88 (-0.37%)

MRK Merck
$84.13 /

+0.43 (+0.51%)

LLY Eli Lilly
$257.69 /

-0.58 (-0.22%)

GSK GlaxoSmithKline
$42.45 /

-0.71 (-1.65%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

SNY Sanofi
$50.90 /

-0.21 (-0.41%)

SBTX Silverback Therapeutics
$8.52 /

-0.185 (-2.13%)

PFE Pfizer
$49.57 /

-0.08 (-0.16%)

MRNA Moderna
$234.20 /

-0.88 (-0.37%)

MRK Merck
$84.13 /

+0.43 (+0.51%)

LLY Eli Lilly
$257.69 /

-0.58 (-0.22%)

GSK GlaxoSmithKline
$42.45 /

-0.71 (-1.65%)

EXAS Exact Sciences
$91.45 /

+1.56 (+1.74%)

AMGN Amgen
$205.37 /

-1.84 (-0.89%)

ALLO Allogene Therapeutics
$19.37 /

+0.54 (+2.87%)

TAK Takeda Pharmaceutical
$14.10 /

-0.32 (-2.22%)

SBTX Silverback Therapeutics
$8.52 /

-0.185 (-2.13%)

PFE Pfizer
$49.57 /

-0.08 (-0.16%)

MRNA Moderna
$234.20 /

-0.88 (-0.37%)

MRK Merck
$84.13 /

+0.43 (+0.51%)

LLY Eli Lilly
$257.69 /

-0.58 (-0.22%)

GSK GlaxoSmithKline
$42.45 /

-0.71 (-1.65%)

AMGN Amgen
$205.37 /

-1.84 (-0.89%)

ALLO Allogene Therapeutics
$19.37 /

+0.54 (+2.87%)

Conference/Events
STAT to hold a virtual summit » 10:37
11/16/21
11/16
10:37
11/16/21
10:37
ALLO

Allogene Therapeutics

$18.84 /

+0.01 (+0.05%)

, AMGN

Amgen

$207.95 /

+0.74 (+0.36%)

, CSLLY

CSL

$113.54 /

+0.98 (+0.87%)

, EXAS

Exact Sciences

$87.99 /

-1.9 (-2.11%)

, GSK

GlaxoSmithKline

$42.52 /

-0.64 (-1.48%)

, LLY

Eli Lilly

$258.29 /

+0.02 (+0.01%)

, MRK

Merck

$84.44 /

+0.74 (+0.88%)

, MRNA

Moderna

$235.87 /

+0.79 (+0.34%)

, PFE

Pfizer

$49.38 /

-0.27 (-0.54%)

, SBTX

Silverback Therapeutics

$8.33 /

-0.375 (-4.31%)

, SNY

Sanofi

$51.24 /

+0.13 (+0.25%)

, TAK

Takeda Pharmaceutical

$14.20 /

-0.22 (-1.53%)

, URGN

UroGen Pharma

$13.73 /

-0.995 (-6.76%)

STAT Summit 2021 to be…

STAT Summit 2021 to be held on November 16-18.Webcast Link

ShowHide Related Items >><<
URGN UroGen Pharma
$13.73 /

-0.995 (-6.76%)

TAK Takeda Pharmaceutical
$14.20 /

-0.22 (-1.53%)

SNY Sanofi
$51.24 /

+0.13 (+0.25%)

SBTX Silverback Therapeutics
$8.33 /

-0.375 (-4.31%)

PFE Pfizer
$49.38 /

-0.27 (-0.54%)

MRNA Moderna
$235.87 /

+0.79 (+0.34%)

MRK Merck
$84.44 /

+0.74 (+0.88%)

LLY Eli Lilly
$258.29 /

+0.02 (+0.01%)

GSK GlaxoSmithKline
$42.52 /

-0.64 (-1.48%)

EXAS Exact Sciences
$87.99 /

-1.9 (-2.11%)

CSLLY CSL
$113.54 /

+0.98 (+0.87%)

AMGN Amgen
$207.95 /

+0.74 (+0.36%)

ALLO Allogene Therapeutics
$18.84 /

+0.01 (+0.05%)

ALLO Allogene Therapeutics
$18.84 /

+0.01 (+0.05%)

10/19/21 Cowen
Allogene Therapeutics assumed with an Outperform at Cowen
10/12/21 JMP Securities
Allogene Therapeutics price target lowered to $27 from $53 at JMP Securities
10/08/21
Fly Intel: Top five analyst downgrades
10/08/21 Jefferies
Jefferies lowers Allogene price target to $30, says 'buy this dip'
AMGN Amgen
$207.95 /

+0.74 (+0.36%)

11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
CSLLY CSL
$113.54 /

+0.98 (+0.87%)

10/05/21 Jefferies
CSL upgraded to Buy from Hold at Jefferies
08/18/21 Jefferies
CSL downgraded to Hold from Buy at Jefferies
06/24/21 Credit Suisse
CSL downgraded to Neutral from Outperform at Credit Suisse
06/23/21 Citi
CSL downgraded to Neutral from Buy at Citi
EXAS Exact Sciences
$87.99 /

-1.9 (-2.11%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
GSK GlaxoSmithKline
$42.52 /

-0.64 (-1.48%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
LLY Eli Lilly
$258.29 /

+0.02 (+0.01%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
MRK Merck
$84.44 /

+0.74 (+0.88%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
MRNA Moderna
$235.87 /

+0.79 (+0.34%)

11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
11/08/21 Wolfe Research
Moderna initiated with an Outperform at Wolfe Research
11/05/21 Jefferies
Moderna price target lowered to $325 from $375 at Jefferies
11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
PFE Pfizer
$49.38 /

-0.27 (-0.54%)

11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
SBTX Silverback Therapeutics
$8.33 /

-0.375 (-4.31%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
SNY Sanofi
$51.24 /

+0.13 (+0.25%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
TAK Takeda Pharmaceutical
$14.20 /

-0.22 (-1.53%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
URGN UroGen Pharma
$13.73 /

-0.995 (-6.76%)

04/27/21 H.C. Wainwright
UroGen Pharma price target lowered to $50 from $57 at H.C. Wainwright
URGN UroGen Pharma
$13.73 /

-0.995 (-6.76%)

SNY Sanofi
$51.24 /

+0.13 (+0.25%)

SBTX Silverback Therapeutics
$8.33 /

-0.375 (-4.31%)

PFE Pfizer
$49.38 /

-0.27 (-0.54%)

MRNA Moderna
$235.87 /

+0.79 (+0.34%)

MRK Merck
$84.44 /

+0.74 (+0.88%)

LLY Eli Lilly
$258.29 /

+0.02 (+0.01%)

GSK GlaxoSmithKline
$42.52 /

-0.64 (-1.48%)

EXAS Exact Sciences
$87.99 /

-1.9 (-2.11%)

AMGN Amgen
$207.95 /

+0.74 (+0.36%)

ALLO Allogene Therapeutics
$18.84 /

+0.01 (+0.05%)

  • 04
    Dec
TAK Takeda Pharmaceutical
$14.20 /

-0.22 (-1.53%)

SNY Sanofi
$51.24 /

+0.13 (+0.25%)

PFE Pfizer
$49.38 /

-0.27 (-0.54%)

MRNA Moderna
$235.87 /

+0.79 (+0.34%)

MRK Merck
$84.44 /

+0.74 (+0.88%)

LLY Eli Lilly
$258.29 /

+0.02 (+0.01%)

GSK GlaxoSmithKline
$42.52 /

-0.64 (-1.48%)

EXAS Exact Sciences
$87.99 /

-1.9 (-2.11%)

TAK Takeda Pharmaceutical
$14.20 /

-0.22 (-1.53%)

SNY Sanofi
$51.24 /

+0.13 (+0.25%)

SBTX Silverback Therapeutics
$8.33 /

-0.375 (-4.31%)

PFE Pfizer
$49.38 /

-0.27 (-0.54%)

MRNA Moderna
$235.87 /

+0.79 (+0.34%)

MRK Merck
$84.44 /

+0.74 (+0.88%)

LLY Eli Lilly
$258.29 /

+0.02 (+0.01%)

GSK GlaxoSmithKline
$42.52 /

-0.64 (-1.48%)

EXAS Exact Sciences
$87.99 /

-1.9 (-2.11%)

AMGN Amgen
$207.95 /

+0.74 (+0.36%)

ALLO Allogene Therapeutics
$18.84 /

+0.01 (+0.05%)

TAK Takeda Pharmaceutical
$14.20 /

-0.22 (-1.53%)

SBTX Silverback Therapeutics
$8.33 /

-0.375 (-4.31%)

PFE Pfizer
$49.38 /

-0.27 (-0.54%)

MRNA Moderna
$235.87 /

+0.79 (+0.34%)

MRK Merck
$84.44 /

+0.74 (+0.88%)

LLY Eli Lilly
$258.29 /

+0.02 (+0.01%)

GSK GlaxoSmithKline
$42.52 /

-0.64 (-1.48%)

AMGN Amgen
$207.95 /

+0.74 (+0.36%)

ALLO Allogene Therapeutics
$18.84 /

+0.01 (+0.05%)

Conference/Events
American Association for the Study of Liver Diseases to hold virtual meeting » 04:55
11/15/21
11/15
04:55
11/15/21
04:55
ABBV

AbbVie

$116.95 /

+0.32 (+0.27%)

, AKRO

Akero Therapeutics

$25.30 /

+0.59 (+2.39%)

, ALBO

Albireo Pharma

$28.98 /

+0.84 (+2.99%)

, ASMB

Assembly Biosciences

$2.89 /

+0.015 (+0.52%)

, AXLA

Axcella Health

$2.97 /

-0.065 (-2.15%)

, BAYRY

Bayer

$14.60 /

-0.02 (-0.14%)

, AZN

AstraZeneca

$58.80 /

-4.105 (-6.53%)

, BY

Byline Bancorp

$27.09 /

-0.48 (-1.74%)

, CBAY

CymaBay

$4.41 /

+0.1 (+2.32%)

, DVAX

Dynavax

$16.95 /

+0.535 (+3.26%)

, JNJ

Johnson & Johnson

$165.02 /

+1.95 (+1.20%)

, LGND

Ligand

$161.34 /

-0.425 (-0.26%)

, RHHBY

Roche

$50.05 /

-0.34 (-0.67%)

, SBTX

Silverback Therapeutics

$8.46 /

+0.055 (+0.65%)

, ICPT

Intercept

$19.04 /

+0.21 (+1.12%)

, GSK

GlaxoSmithKline

$43.35 /

+0.13 (+0.30%)

, GNFT

Genfit

$3.53 /

-0.02 (-0.56%)

, GILD

Gilead

$67.48 /

+0.07 (+0.10%)

, ETNB

89bio

$17.69 /

-0.16 (-0.90%)

, ENTA

Enanta

$91.19 /

+0.31 (+0.34%)

, LPCN

Lipocine

$1.20 /

+0.015 (+1.27%)

, TAK

Takeda Pharmaceutical

$14.42 /

+0.23 (+1.62%)

, MRK

Merck

$84.02 /

+ (+0.00%)

, NVO

Novo Nordisk

$113.11 /

-0.32 (-0.28%)

, NVS

Novartis

$82.50 /

-0.34 (-0.41%)

, PFE

Pfizer

$49.74 /

-0.42 (-0.84%)

, VRTX

Vertex Pharmaceuticals

$187.26 /

+1.48 (+0.80%)

, VIR

Vir Biotechnology

$33.10 /

+0.01 (+0.03%)

The Virtual Liver Meeting…

The Virtual Liver Meeting 2021 to be held on November 12-15.Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GNFT Genfit
$3.53 /

-0.02 (-0.56%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

ETNB 89bio
$17.69 /

-0.16 (-0.90%)

ENTA Enanta
$91.19 /

+0.31 (+0.34%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
10/29/21 Piper Sandler
AbbVie price target raised to $129 from $124 at Piper Sandler
10/19/21 Morgan Stanley
Regenxbio assumed with an Overweight at Morgan Stanley
10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
09/10/21 BofA
Akero Therapeutics initiated with a Buy at BofA
08/16/21 H.C. Wainwright
Akero Therapeutics price target lowered to $64 from $68 at H.C. Wainwright
ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

11/05/21 H.C. Wainwright
H.C. Wainwright ups Albireo target to $80 on 'strong' Bylvay launch
09/16/21 Wedbush
Albireo Pharma price target raised to $84 from $82 at Wedbush
08/25/21 Piper Sandler
Albireo Pharma weakness brings buying opportunity, says Piper Sandler
08/02/21 Wedbush
Albireo Pharma removed from Best Ideas List at Wedbush
ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

09/13/21 H.C. Wainwright
Assembly Biosciences initiated with a Neutral at H.C. Wainwright
09/03/21 Mizuho
Assembly stopping H2158 development not necessarily bad thing, says Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
09/02/21 William Blair
William Blair downgrades Assembly Biosciences on H2158 discontinuation
AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

09/13/21 Hovde Group
Byline Bancorp initiated with an Outperform at Hovde Group
08/02/21
Fly Intel: Top five analyst downgrades
08/02/21 Stephens
Byline Bancorp downgraded to Equal Weight at Stephens following outperformance
08/02/21 Stephens
Byline Bancorp downgraded to Equal Weight from Overweight at Stephens
CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

11/10/21 Piper Sandler
Piper Sandler says buyer of CymaBay at low valuation
08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

08/31/21 H.C. Wainwright
Dynavax price target raised to $23 from $20 at H.C. Wainwright
08/05/21 Goldman Sachs
Dynavax initiated with a Buy at Goldman Sachs
08/05/21 H.C. Wainwright
Dynavax price target raised to $20 from $16 at H.C. Wainwright
02/08/21 Evercore ISI
Dynavax had 'big vaccine update week,' says Evercore ISI
JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
LGND Ligand
$161.34 /

-0.425 (-0.26%)

09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
07/30/21 Roth Capital
Ligand price target lowered to $190 from $200 at Roth Capital
05/04/21 Barclays
Ligand price target lowered to $190 from $198 at Barclays
RHHBY Roche
$50.05 /

-0.34 (-0.67%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
ICPT Intercept
$19.04 /

+0.21 (+1.12%)

11/04/21 B. Riley
Intercept price target raised to $25 from $22 at B. Riley
08/20/21
Fly Intel: Top five analyst downgrades
08/20/21 Goldman Sachs
Intercept downgraded to Sell from Neutral at Goldman Sachs
08/03/21 B. Riley
Intercept price target raised to $22 from $18 at B. Riley
GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
GNFT Genfit
$3.53 /

-0.02 (-0.56%)

09/30/21 H.C. Wainwright
Genfit price target lowered to $7 from $8 at H.C. Wainwright
04/05/21 SVB Leerink
Genfit price target lowered to $15 from $20 at SVB Leerink
02/12/21 Bryan Garnier
Genfit upgraded to Buy from Neutral at Bryan Garnier
11/23/20 H.C. Wainwright
Genfit convertible bond moves should improve flexibility, says H.C. Wainwright
GILD Gilead
$67.48 /

+0.07 (+0.10%)

11/12/21 Morgan Stanley
Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update
11/09/21 Barclays
Arcus Biosciences price target raised to $48 from $45 at Barclays
11/09/21 Mizuho
Arcus Biosciences price target raised to $51 from $43 at Mizuho
10/19/21 Cowen
Gilead assumed with an Outperform at Cowen
ETNB 89bio
$17.69 /

-0.16 (-0.90%)

11/12/21 RBC Capital
89bio price target lowered to $42 from $46 at RBC Capital
10/26/21 Cantor Fitzgerald
89bio assumed with an Overweight at Cantor Fitzgerald
07/29/21 BTIG
89bio assumed with a Buy at BTIG
05/25/21
Fly Intel: Top five analyst downgrades
ENTA Enanta
$91.19 /

+0.31 (+0.34%)

11/08/21 Baird
Enanta price target raised to $130 from $71 at Baird
10/20/21 RBC Capital
Enanta price target raised to $74 from $58 at RBC Capital
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/06/21 Jefferies
Enanta initiated with a Buy at Jefferies
LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

08/26/21 H.C. Wainwright
Lipocine price target raised to $3.50 from $2.50 at H.C. Wainwright
06/24/21 Cantor Fitzgerald
Lipocine initiated with an Overweight at Cantor Fitzgerald
12/10/20 Ladenburg
Lipocine upgraded to Buy after tentative Tlando approval at Ladenburg
12/10/20 Ladenburg
Lipocine upgraded to Buy from Neutral at Ladenburg
TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$84.02 /

+ (+0.00%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

11/11/21 UBS
Novo Nordisk price target raised to DKK 725 from DKK 630 at UBS
11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
NVS Novartis
$82.50 /

-0.34 (-0.41%)

11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
11/05/21 UBS
Novartis downgraded to Neutral from Buy at UBS
10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
PFE Pfizer
$49.74 /

-0.42 (-0.84%)

11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/05/21 Deutsche Bank
Grifols downgraded to Hold from Buy at Deutsche Bank
10/18/21 Piper Sandler
Vertex's VX-880 achieves efficacy in Type 1 diabetes patient, says Piper Sandler
09/09/21
Fly Intel: Top five analyst downgrades
VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
10/25/21 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
09/22/21
Fly Intel: Top five analyst downgrades
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

ETNB 89bio
$17.69 /

-0.16 (-0.90%)

ENTA Enanta
$91.19 /

+0.31 (+0.34%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

  • 26
    Jan
  • 04
    Dec
TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

MRK Merck
$84.02 /

+ (+0.00%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

MRK Merck
$84.02 /

+ (+0.00%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

Conference/Events
American Association for the Study of Liver Diseases to hold virtual meeting » 04:55
11/14/21
11/14
04:55
11/14/21
04:55
ABBV

AbbVie

$116.95 /

+0.32 (+0.27%)

, AKRO

Akero Therapeutics

$25.30 /

+0.59 (+2.39%)

, ALBO

Albireo Pharma

$28.98 /

+0.84 (+2.99%)

, ASMB

Assembly Biosciences

$2.89 /

+0.015 (+0.52%)

, AXLA

Axcella Health

$2.97 /

-0.065 (-2.15%)

, BAYRY

Bayer

$14.60 /

-0.02 (-0.14%)

, AZN

AstraZeneca

$58.80 /

-4.105 (-6.53%)

, BY

Byline Bancorp

$27.09 /

-0.48 (-1.74%)

, CBAY

CymaBay

$4.41 /

+0.1 (+2.32%)

, DVAX

Dynavax

$16.95 /

+0.535 (+3.26%)

, JNJ

Johnson & Johnson

$165.02 /

+1.95 (+1.20%)

, LGND

Ligand

$161.34 /

-0.425 (-0.26%)

, RHHBY

Roche

$50.05 /

-0.34 (-0.67%)

, SBTX

Silverback Therapeutics

$8.46 /

+0.055 (+0.65%)

, ICPT

Intercept

$19.04 /

+0.21 (+1.12%)

, GSK

GlaxoSmithKline

$43.35 /

+0.13 (+0.30%)

, GNFT

Genfit

$3.53 /

-0.02 (-0.56%)

, GILD

Gilead

$67.48 /

+0.07 (+0.10%)

, ETNB

89bio

$17.69 /

-0.16 (-0.90%)

, ENTA

Enanta

$91.19 /

+0.31 (+0.34%)

, LPCN

Lipocine

$1.20 /

+0.015 (+1.27%)

, TAK

Takeda Pharmaceutical

$14.42 /

+0.23 (+1.62%)

, MRK

Merck

$84.02 /

+ (+0.00%)

, NVO

Novo Nordisk

$113.11 /

-0.32 (-0.28%)

, NVS

Novartis

$82.50 /

-0.34 (-0.41%)

, PFE

Pfizer

$49.74 /

-0.42 (-0.84%)

, VRTX

Vertex Pharmaceuticals

$187.26 /

+1.48 (+0.80%)

, VIR

Vir Biotechnology

$33.10 /

+0.01 (+0.03%)

The Virtual Liver Meeting…

The Virtual Liver Meeting 2021 to be held on November 12-15.Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GNFT Genfit
$3.53 /

-0.02 (-0.56%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

ETNB 89bio
$17.69 /

-0.16 (-0.90%)

ENTA Enanta
$91.19 /

+0.31 (+0.34%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
10/29/21 Piper Sandler
AbbVie price target raised to $129 from $124 at Piper Sandler
10/19/21 Morgan Stanley
Regenxbio assumed with an Overweight at Morgan Stanley
10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
09/10/21 BofA
Akero Therapeutics initiated with a Buy at BofA
08/16/21 H.C. Wainwright
Akero Therapeutics price target lowered to $64 from $68 at H.C. Wainwright
ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

11/05/21 H.C. Wainwright
H.C. Wainwright ups Albireo target to $80 on 'strong' Bylvay launch
09/16/21 Wedbush
Albireo Pharma price target raised to $84 from $82 at Wedbush
08/25/21 Piper Sandler
Albireo Pharma weakness brings buying opportunity, says Piper Sandler
08/02/21 Wedbush
Albireo Pharma removed from Best Ideas List at Wedbush
ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

09/13/21 H.C. Wainwright
Assembly Biosciences initiated with a Neutral at H.C. Wainwright
09/03/21 Mizuho
Assembly stopping H2158 development not necessarily bad thing, says Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
09/02/21 William Blair
William Blair downgrades Assembly Biosciences on H2158 discontinuation
AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

09/13/21 Hovde Group
Byline Bancorp initiated with an Outperform at Hovde Group
08/02/21
Fly Intel: Top five analyst downgrades
08/02/21 Stephens
Byline Bancorp downgraded to Equal Weight at Stephens following outperformance
08/02/21 Stephens
Byline Bancorp downgraded to Equal Weight from Overweight at Stephens
CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

11/10/21 Piper Sandler
Piper Sandler says buyer of CymaBay at low valuation
08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

08/31/21 H.C. Wainwright
Dynavax price target raised to $23 from $20 at H.C. Wainwright
08/05/21 Goldman Sachs
Dynavax initiated with a Buy at Goldman Sachs
08/05/21 H.C. Wainwright
Dynavax price target raised to $20 from $16 at H.C. Wainwright
02/08/21 Evercore ISI
Dynavax had 'big vaccine update week,' says Evercore ISI
JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
LGND Ligand
$161.34 /

-0.425 (-0.26%)

09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
07/30/21 Roth Capital
Ligand price target lowered to $190 from $200 at Roth Capital
05/04/21 Barclays
Ligand price target lowered to $190 from $198 at Barclays
RHHBY Roche
$50.05 /

-0.34 (-0.67%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
ICPT Intercept
$19.04 /

+0.21 (+1.12%)

11/04/21 B. Riley
Intercept price target raised to $25 from $22 at B. Riley
08/20/21
Fly Intel: Top five analyst downgrades
08/20/21 Goldman Sachs
Intercept downgraded to Sell from Neutral at Goldman Sachs
08/03/21 B. Riley
Intercept price target raised to $22 from $18 at B. Riley
GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
GNFT Genfit
$3.53 /

-0.02 (-0.56%)

09/30/21 H.C. Wainwright
Genfit price target lowered to $7 from $8 at H.C. Wainwright
04/05/21 SVB Leerink
Genfit price target lowered to $15 from $20 at SVB Leerink
02/12/21 Bryan Garnier
Genfit upgraded to Buy from Neutral at Bryan Garnier
11/23/20 H.C. Wainwright
Genfit convertible bond moves should improve flexibility, says H.C. Wainwright
GILD Gilead
$67.48 /

+0.07 (+0.10%)

11/12/21 Morgan Stanley
Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update
11/09/21 Barclays
Arcus Biosciences price target raised to $48 from $45 at Barclays
11/09/21 Mizuho
Arcus Biosciences price target raised to $51 from $43 at Mizuho
10/19/21 Cowen
Gilead assumed with an Outperform at Cowen
ETNB 89bio
$17.69 /

-0.16 (-0.90%)

11/12/21 RBC Capital
89bio price target lowered to $42 from $46 at RBC Capital
10/26/21 Cantor Fitzgerald
89bio assumed with an Overweight at Cantor Fitzgerald
07/29/21 BTIG
89bio assumed with a Buy at BTIG
05/25/21
Fly Intel: Top five analyst downgrades
ENTA Enanta
$91.19 /

+0.31 (+0.34%)

11/08/21 Baird
Enanta price target raised to $130 from $71 at Baird
10/20/21 RBC Capital
Enanta price target raised to $74 from $58 at RBC Capital
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/06/21 Jefferies
Enanta initiated with a Buy at Jefferies
LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

08/26/21 H.C. Wainwright
Lipocine price target raised to $3.50 from $2.50 at H.C. Wainwright
06/24/21 Cantor Fitzgerald
Lipocine initiated with an Overweight at Cantor Fitzgerald
12/10/20 Ladenburg
Lipocine upgraded to Buy after tentative Tlando approval at Ladenburg
12/10/20 Ladenburg
Lipocine upgraded to Buy from Neutral at Ladenburg
TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$84.02 /

+ (+0.00%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

11/11/21 UBS
Novo Nordisk price target raised to DKK 725 from DKK 630 at UBS
11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
NVS Novartis
$82.50 /

-0.34 (-0.41%)

11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
11/05/21 UBS
Novartis downgraded to Neutral from Buy at UBS
10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
PFE Pfizer
$49.74 /

-0.42 (-0.84%)

11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/05/21 Deutsche Bank
Grifols downgraded to Hold from Buy at Deutsche Bank
10/18/21 Piper Sandler
Vertex's VX-880 achieves efficacy in Type 1 diabetes patient, says Piper Sandler
09/09/21
Fly Intel: Top five analyst downgrades
VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
10/25/21 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
09/22/21
Fly Intel: Top five analyst downgrades
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

ETNB 89bio
$17.69 /

-0.16 (-0.90%)

ENTA Enanta
$91.19 /

+0.31 (+0.34%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

  • 26
    Jan
  • 04
    Dec
TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

MRK Merck
$84.02 /

+ (+0.00%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

MRK Merck
$84.02 /

+ (+0.00%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

Conference/Events
American Association for the Study of Liver Diseases to hold virtual meeting » 04:55
11/13/21
11/13
04:55
11/13/21
04:55
ABBV

AbbVie

$116.95 /

+0.32 (+0.27%)

, AKRO

Akero Therapeutics

$25.30 /

+0.59 (+2.39%)

, ALBO

Albireo Pharma

$28.98 /

+0.84 (+2.99%)

, ASMB

Assembly Biosciences

$2.89 /

+0.015 (+0.52%)

, AXLA

Axcella Health

$2.97 /

-0.065 (-2.15%)

, BAYRY

Bayer

$14.60 /

-0.02 (-0.14%)

, AZN

AstraZeneca

$58.80 /

-4.105 (-6.53%)

, BY

Byline Bancorp

$27.09 /

-0.48 (-1.74%)

, CBAY

CymaBay

$4.41 /

+0.1 (+2.32%)

, DVAX

Dynavax

$16.95 /

+0.535 (+3.26%)

, JNJ

Johnson & Johnson

$165.02 /

+1.95 (+1.20%)

, LGND

Ligand

$161.34 /

-0.425 (-0.26%)

, RHHBY

Roche

$50.05 /

-0.34 (-0.67%)

, SBTX

Silverback Therapeutics

$8.46 /

+0.055 (+0.65%)

, ICPT

Intercept

$19.04 /

+0.21 (+1.12%)

, GSK

GlaxoSmithKline

$43.35 /

+0.13 (+0.30%)

, GNFT

Genfit

$3.53 /

-0.02 (-0.56%)

, GILD

Gilead

$67.48 /

+0.07 (+0.10%)

, ETNB

89bio

$17.69 /

-0.16 (-0.90%)

, ENTA

Enanta

$91.19 /

+0.31 (+0.34%)

, LPCN

Lipocine

$1.20 /

+0.015 (+1.27%)

, TAK

Takeda Pharmaceutical

$14.42 /

+0.23 (+1.62%)

, MRK

Merck

$84.02 /

+ (+0.00%)

, NVO

Novo Nordisk

$113.11 /

-0.32 (-0.28%)

, NVS

Novartis

$82.50 /

-0.34 (-0.41%)

, PFE

Pfizer

$49.74 /

-0.42 (-0.84%)

, VRTX

Vertex Pharmaceuticals

$187.26 /

+1.48 (+0.80%)

, VIR

Vir Biotechnology

$33.10 /

+0.01 (+0.03%)

The Virtual Liver Meeting…

The Virtual Liver Meeting 2021 to be held on November 12-15.Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GNFT Genfit
$3.53 /

-0.02 (-0.56%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

ETNB 89bio
$17.69 /

-0.16 (-0.90%)

ENTA Enanta
$91.19 /

+0.31 (+0.34%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
10/29/21 Piper Sandler
AbbVie price target raised to $129 from $124 at Piper Sandler
10/19/21 Morgan Stanley
Regenxbio assumed with an Overweight at Morgan Stanley
10/05/21 Piper Sandler
Biohaven Pharmaceutical price target raised to $156 from $140 at Piper Sandler
AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

10/19/21
Fly Intel: Top five analyst downgrades
10/19/21 Morgan Stanley
Akero Therapeutics assumed at Equal Weight from Overweight at Morgan Stanley
09/10/21 BofA
Akero Therapeutics initiated with a Buy at BofA
08/16/21 H.C. Wainwright
Akero Therapeutics price target lowered to $64 from $68 at H.C. Wainwright
ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

11/05/21 H.C. Wainwright
H.C. Wainwright ups Albireo target to $80 on 'strong' Bylvay launch
09/16/21 Wedbush
Albireo Pharma price target raised to $84 from $82 at Wedbush
08/25/21 Piper Sandler
Albireo Pharma weakness brings buying opportunity, says Piper Sandler
08/02/21 Wedbush
Albireo Pharma removed from Best Ideas List at Wedbush
ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

09/13/21 H.C. Wainwright
Assembly Biosciences initiated with a Neutral at H.C. Wainwright
09/03/21 Mizuho
Assembly stopping H2158 development not necessarily bad thing, says Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
09/02/21 William Blair
William Blair downgrades Assembly Biosciences on H2158 discontinuation
AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

09/13/21 Hovde Group
Byline Bancorp initiated with an Outperform at Hovde Group
08/02/21
Fly Intel: Top five analyst downgrades
08/02/21 Stephens
Byline Bancorp downgraded to Equal Weight at Stephens following outperformance
08/02/21 Stephens
Byline Bancorp downgraded to Equal Weight from Overweight at Stephens
CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

11/10/21 Piper Sandler
Piper Sandler says buyer of CymaBay at low valuation
08/18/21 B. Riley
CymaBay price target lowered to $10 from $13 at B. Riley
08/03/21 H.C. Wainwright
CymaBay price target lowered to $12 from $13 at H.C. Wainwright
08/02/21 Piper Sandler
CymaBay agreement removes 'key pressure point,' says Piper Sandler
DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

08/31/21 H.C. Wainwright
Dynavax price target raised to $23 from $20 at H.C. Wainwright
08/05/21 Goldman Sachs
Dynavax initiated with a Buy at Goldman Sachs
08/05/21 H.C. Wainwright
Dynavax price target raised to $20 from $16 at H.C. Wainwright
02/08/21 Evercore ISI
Dynavax had 'big vaccine update week,' says Evercore ISI
JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
LGND Ligand
$161.34 /

-0.425 (-0.26%)

09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
07/30/21 Roth Capital
Ligand price target lowered to $190 from $200 at Roth Capital
05/04/21 Barclays
Ligand price target lowered to $190 from $198 at Barclays
RHHBY Roche
$50.05 /

-0.34 (-0.67%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
03/30/21 Goldman Sachs
Silverback price target raised to $48 from $43 at Goldman Sachs
ICPT Intercept
$19.04 /

+0.21 (+1.12%)

11/04/21 B. Riley
Intercept price target raised to $25 from $22 at B. Riley
08/20/21
Fly Intel: Top five analyst downgrades
08/20/21 Goldman Sachs
Intercept downgraded to Sell from Neutral at Goldman Sachs
08/03/21 B. Riley
Intercept price target raised to $22 from $18 at B. Riley
GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
GNFT Genfit
$3.53 /

-0.02 (-0.56%)

09/30/21 H.C. Wainwright
Genfit price target lowered to $7 from $8 at H.C. Wainwright
04/05/21 SVB Leerink
Genfit price target lowered to $15 from $20 at SVB Leerink
02/12/21 Bryan Garnier
Genfit upgraded to Buy from Neutral at Bryan Garnier
11/23/20 H.C. Wainwright
Genfit convertible bond moves should improve flexibility, says H.C. Wainwright
GILD Gilead
$67.48 /

+0.07 (+0.10%)

11/12/21 Morgan Stanley
Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update
11/09/21 Barclays
Arcus Biosciences price target raised to $48 from $45 at Barclays
11/09/21 Mizuho
Arcus Biosciences price target raised to $51 from $43 at Mizuho
10/19/21 Cowen
Gilead assumed with an Outperform at Cowen
ETNB 89bio
$17.69 /

-0.16 (-0.90%)

11/12/21 RBC Capital
89bio price target lowered to $42 from $46 at RBC Capital
10/26/21 Cantor Fitzgerald
89bio assumed with an Overweight at Cantor Fitzgerald
07/29/21 BTIG
89bio assumed with a Buy at BTIG
05/25/21
Fly Intel: Top five analyst downgrades
ENTA Enanta
$91.19 /

+0.31 (+0.34%)

11/08/21 Baird
Enanta price target raised to $130 from $71 at Baird
10/20/21 RBC Capital
Enanta price target raised to $74 from $58 at RBC Capital
10/19/21 Roth Capital
Enanta drug 'naturally more potent' than Merck's antiviral, says Roth Capital
10/06/21 Jefferies
Enanta initiated with a Buy at Jefferies
LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

08/26/21 H.C. Wainwright
Lipocine price target raised to $3.50 from $2.50 at H.C. Wainwright
06/24/21 Cantor Fitzgerald
Lipocine initiated with an Overweight at Cantor Fitzgerald
12/10/20 Ladenburg
Lipocine upgraded to Buy after tentative Tlando approval at Ladenburg
12/10/20 Ladenburg
Lipocine upgraded to Buy from Neutral at Ladenburg
TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$84.02 /

+ (+0.00%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

11/11/21 UBS
Novo Nordisk price target raised to DKK 725 from DKK 630 at UBS
11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
NVS Novartis
$82.50 /

-0.34 (-0.41%)

11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
11/05/21 UBS
Novartis downgraded to Neutral from Buy at UBS
10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
PFE Pfizer
$49.74 /

-0.42 (-0.84%)

11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
11/05/21 Deutsche Bank
Grifols downgraded to Hold from Buy at Deutsche Bank
10/18/21 Piper Sandler
Vertex's VX-880 achieves efficacy in Type 1 diabetes patient, says Piper Sandler
09/09/21
Fly Intel: Top five analyst downgrades
VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
10/25/21 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
09/22/21
Fly Intel: Top five analyst downgrades
VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LPCN Lipocine
$1.20 /

+0.015 (+1.27%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

ETNB 89bio
$17.69 /

-0.16 (-0.90%)

ENTA Enanta
$91.19 /

+0.31 (+0.34%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

CBAY CymaBay
$4.41 /

+0.1 (+2.32%)

BY Byline Bancorp
$27.09 /

-0.48 (-1.74%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ASMB Assembly Biosciences
$2.89 /

+0.015 (+0.52%)

ALBO Albireo Pharma
$28.98 /

+0.84 (+2.99%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

  • 26
    Jan
  • 04
    Dec
TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

MRK Merck
$84.02 /

+ (+0.00%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

VIR Vir Biotechnology
$33.10 /

+0.01 (+0.03%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

RHHBY Roche
$50.05 /

-0.34 (-0.67%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

NVO Novo Nordisk
$113.11 /

-0.32 (-0.28%)

MRK Merck
$84.02 /

+ (+0.00%)

LGND Ligand
$161.34 /

-0.425 (-0.26%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

ICPT Intercept
$19.04 /

+0.21 (+1.12%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

BAYRY Bayer
$14.60 /

-0.02 (-0.14%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

AKRO Akero Therapeutics
$25.30 /

+0.59 (+2.39%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

VRTX Vertex Pharmaceuticals
$187.26 /

+1.48 (+0.80%)

TAK Takeda Pharmaceutical
$14.42 /

+0.23 (+1.62%)

SBTX Silverback Therapeutics
$8.46 /

+0.055 (+0.65%)

PFE Pfizer
$49.74 /

-0.42 (-0.84%)

NVS Novartis
$82.50 /

-0.34 (-0.41%)

MRK Merck
$84.02 /

+ (+0.00%)

JNJ Johnson & Johnson
$165.02 /

+1.95 (+1.20%)

GSK GlaxoSmithKline
$43.35 /

+0.13 (+0.30%)

GILD Gilead
$67.48 /

+0.07 (+0.10%)

DVAX Dynavax
$16.95 /

+0.535 (+3.26%)

AZN AstraZeneca
$58.80 /

-4.105 (-6.53%)

AXLA Axcella Health
$2.97 /

-0.065 (-2.15%)

ABBV AbbVie
$116.95 /

+0.32 (+0.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.